These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34440251)

  • 21. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
    Sebio A; Wilky BA; Keedy VL; Jones RL
    Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
    Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging mechanisms of immunotherapy resistance in sarcomas.
    Florou V; Wilky BA
    Cancer Drug Resist; 2022; 5(1):199-213. PubMed ID: 35582530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
    Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD
    Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
    Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
    Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
    Seong G; D'Angelo SP
    Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the Management of Pediatric Sarcomas.
    Hernandez Tejada FN; Zamudio A; Marques-Piubelli ML; Cuglievan B; Harrison D
    Curr Oncol Rep; 2020 Nov; 23(1):3. PubMed ID: 33196879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade.
    Hong DC; Yang J; Sun C; Liu YT; Shen LJ; Xu BS; Que Y; Xia X; Zhang X
    Clin Cancer Res; 2023 Aug; 29(15):2869-2884. PubMed ID: 37184976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immune subtypes and landscape of sarcomas.
    Weng W; Yu L; Li Z; Tan C; Lv J; Lao IW; Hu W; Deng Z; Liu Z; Wang J; Xu M
    BMC Immunol; 2022 Sep; 23(1):46. PubMed ID: 36153483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the landscape of immunotherapy approaches in sarcomas.
    Pilavaki P; Panagi M; Arifi S; Jones RL; Stylianopoulos T; Constantinidou A
    Front Oncol; 2022; 12():1069963. PubMed ID: 36686827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarcoma immunotherapy: past approaches and future directions.
    D'Angelo SP; Tap WD; Schwartz GK; Carvajal RD
    Sarcoma; 2014; 2014():391967. PubMed ID: 24778572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.
    Anzar I; Malone B; Samarakoon P; Vardaxis I; Simovski B; Fontenelle H; Meza-Zepeda LA; Stratford R; Keung EZ; Burgess M; Tawbi HA; Myklebost O; Clancy T
    Front Immunol; 2023; 14():1226445. PubMed ID: 37799721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.
    Marritt KL; Hildebrand KM; Hildebrand KN; Singla AK; Zemp FJ; Mahoney DJ; Jirik FR; Monument MJ
    Front Immunol; 2022; 13():1087991. PubMed ID: 36700206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy.
    Zhang Z; Chen L; Chen H; Zhao J; Li K; Sun J; Zhou M
    EBioMedicine; 2022 Sep; 83():104207. PubMed ID: 35961204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in immune checkpoint inhibitors for bone sarcoma therapy.
    Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
    J Bone Oncol; 2019 Apr; 15():100221. PubMed ID: 30775238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
    Crombé A; Roulleau-Dugage M; Italiano A
    Cancer Commun (Lond); 2022 Dec; 42(12):1288-1313. PubMed ID: 36260064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.